All In Biotech

Drug Trial Radar · NCT06383013

BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

May 1, 2024

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Blue Blood Biotech Corp.Industry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.

Conditions

  • Diabetic Foot Ulcer

Interventions

  • BB-101Biological

    Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy EvaluationTime frame: 4 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Shin Kong Wu Ho-Su Memorial Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

    Taipei, Taiwan · Recruiting

  • Wanfang Hospital

    Taipei, Taiwan · Not yet recruiting

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.